natgillin/translations-raw huggingface dataset:
Stop taking Icandra for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal.
Za kratek čas prenehajte jemati zdravilo Icandra, če imate stanje, ki je lahko povezano z dehidracijo (znatna izguba telesnih tekočin), kot je hudo bruhanje, driska, zvišana telesna temperatura, izpostavljenost vročini ali če pijete manj tekočine, kot običajno.
If pancreatitis is suspected, vildagliptin should be discontinued; if acute pancreatitis is confirmed, vildagliptin should not be restarted.
Če obstaja sum na pankreatitis, je potrebno prenehati z jemanjem vildagliptina, če pa je diagnoza akutnega pankreatitisa potrjena, bolnik ne sme ponovno začeti z jemanjem vildagliptina.
If you take too many Icandra tablets, or if someone else takes your tablets, talk to a doctor or pharmacist immediately.
Če ste vzeli večji odmerek zdravila Icandra, kot bi smeli Če ste vzeli preveč tablet zdravila Icandra ali če kdo drug vzame vaše tablete, se takoj obrnite na zdravnika ali farmacevta.
Avoid excessive alcohol intake while taking Icandra since this may increase the risk of lactic acidosis (please see section “Warnings and precautions”).
Med jemanjem zdravila Icandra ne uživajte čezmernih količin alkohola, saj lahko to poveča tveganje za laktacidozo (glejte poglavje “Opozorila in previdnostni ukrepi”).
Icandra is not a substitute for insulin in insulin-requiring patients and should not be used in patients with type 1 diabetes.
Zdravilo Icandra ne more nadomestiti zdravljenja z insulinom pri bolnikih, ki potrebujejo insulin, in se ga ne sme uporabljati pri bolnikih z diabetesom tipa 1.
There are no adequate data from the use of Icandra in pregnant women.
Ni zadostnih podatkov o uporabi zdravila Icandra pri nosečnicah.
No studies on the effect on human fertility have been conducted for Icandra (see section 5.3).
Študij o vplivu zdravila Icandra na plodnost pri ljudeh niso izvajali (glejte poglavje 5.3).
- Do not use Icandra if you are pregnant or breast-feeding (see also “Do not take Icandra”).
- Če ste noseči ali dojite, ne smete uporabljati zdravila Icandra (glejte tudi “Ne jemljite zdravila Icandra”).
What you need to know before you take Icandra
Kaj morate vedeti, preden boste vzeli zdravilo Icandra
Driving and using machines If you feel dizzy while taking Icandra, do not drive or use any tools or machines.
Vpliv na sposobnost upravljanja vozil in strojev Če ste med jemanjem zdravila Icandra omotični, ne vozite avtomobila in ne upravljajte z orodji in stroji.
Other medicines and Icandra
Druga zdravila in zdravilo Icandra
You should stop taking Icandra and see your doctor immediately if you experience the following side effects:
Prenehajte jemati zdravilo Icandra in takoj obiščite zdravnika, če se pri vas pojavijo naslednji neželeni učinki:
Due to both the potential risk of neonate hypoglycaemia related to metformin and the lack of human data with vildagliptin, Icandra should not be used during breast-feeding (see section 4.3).
Tako zaradi potencialnega tveganja, da bi pri novorojenčku zaradi metformina prišlo do hipoglikemije, kot tudi zaradi pomanjkanja podatkov o vildagliptinu pri ljudeh, se zdravila Icandra med dojenjem ne sme uporabljati (glejte poglavje 4.3).
Metformin is contraindicated in patients with GFR < 30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function (see section 4.3).
Metformin je kontraindiciran pri bolnikih z GFR< 30 ml/min in ga je treba začasno ukiniti, če se pojavijo stanja, ki spremenijo delovanje ledvic (glejte poglavje 4.3).
• Lactic acidosis (very rare: may affect up to 1 user in 10,000): Icandra may cause a very rare, but very serious side effect called lactic acidosis (see section “Warnings and precautions”).
• laktacidoza (zelo redek: pojavi se lahko pri do 1 od 10.000 bolnikov) Zdravilo Icandra lahko povzroči zelo redek, a zelo resen neželeni učinek, imenovan laktacidoza (glejte poglavje "Opozorila in previdnostni ukrepi").
What Icandra is and what it is used for What you need to know before you take Icandra How to take Icandra
Kaj je zdravilo Icandra in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Icandra Kako jemati zdravilo Icandra Možni neželeni učinki
The rate and extent of absorption of metformin from Icandra 50 mg/1000 mg were decreased when given with food as reflected by the decrease in Cmax by 26%, AUC by 7% and delayed Tmax (2.0 to 4.0 h).
Hitrost in obseg absorpcije metformina iz zdravila Icandra 50 mg/1000 mg pa sta bili pri jemanju s hrano zmanjšani, kar se je odražalo na znižanju Cmax za 26 %, zmanjšanju AUC za 7 % in na podaljšanem Tmax (2,0 do 4,0 ure).
Stop taking Icandra and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma.
Takoj prenehajte jemati zdravilo Icandra in se obrnite na zdravnika ali najbližjo bolnišnico, če se pojavijo nekateri od simptomov laktacidoze, saj lahko to stanje vodi v komo.
The active substances of Icandra, vildagliptin and metformin, belong to a group of medicines called “oral antidiabetics”.
Zdravilni učinkovini v zdravilu Icandra, vildagliptin in metformin, sodita v skupino zdravil, ki se imenujejo “peroralni antidiabetiki”.
What Icandra contains - The active substances are vildagliptin and metformin hydrochloride.
Kaj vsebuje zdravilo Icandra - Učinkovini sta vildagliptin in metforminijev klorid.
In particular, if you are following a diabetic weight control diet, continue with this while you are taking Icandra.
Še posebno če se držite diete za uravnavanje telesne mase za diabetike, z dieto nadaljujte tudi v obdobju jemanja zdravila Icandra.
• Liver disease (hepatitis) (rare): Symptoms include yellow skin and eyes, nausea, loss of appetite or dark-coloured urine, which may indicate liver disease (hepatitis).
• bolezen jeter (hepatitis) (redek): simptomi vključujejo rumena koža in oči, slabost, izguba apetita ali temno obarvan urin, kar lahko kaže na bolezen jeter (hepatitis) );
Lactic acidosis, a very rare but serious metabolic complication, most often occurs at acute worsening of renal function, or cardiorespiratory illness or sepsis.
Laktacidoza, zelo redek a resen presnovni zaplet, se najpogosteje pojavi ob akutnem poslabšanju delovanja ledvic, ob kardiorespiratorni bolezni ali sepsi.
Symptoms of lactic acidosis include: vomiting stomach ache (abdominal pain) muscle cramps a general feeling of not being well with severe tiredness difficulty in breathing reduced body temperature and heartbeat
Simptomi laktacidoze vključujejo: bruhanje bolečina v trebuhu (abdominalna bolečina) mišične krče splošno slabo počutje s hudo utrujenostjo težave z dihanjem znižano telesno temperaturo in počasen srčni utrip
If necessary, the dosage of Icandra may need to be adjusted during concomitant therapy and on its discontinuation.
Če je potrebno, je mogoče prilagoditi odmerek zdravila Icandra v času sočasne uporabe drugega zdravila in ob njegovi ukinitvi.
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Eucreas before or at the time of the injection.
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Icandra.
Following withdrawal of treatment with Icandra and LFT normalisation, treatment with Icandra should not be re-initiated.
Po prekinitvi zdravljenja z zdravilom Icandra in normalizaciji vrednosti jetrnih testov se zdravljenja z zdravilom Icandra ne sme ponovno uvesti.
If this happens you must stop taking Icandra and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.
V tem primeru morate prenehati jemati zdravilo Icandra in se takoj obrniti na zdravnika ali najbližjo bolnišnico, saj lahko laktacidoza vodi v komo;
There have been no therapeutic clinical trials conducted with Icandra.
Terapevtskih kliničnih preskušanj z zdravilom Icandra niso izvajali.
As metformin is excreted via the kidney, and elderly patients have a tendency to decreased renal function, elderly patients taking Icandra should have their renal function monitored regularly (see sections 4.4 and 5.2).
Metformin se izloča preko ledvic, pri starejših bolnikih pa je delovanje ledvic pogosto zmanjšano, zato je treba starejšim bolnikom, ki jemljejo zdravilo Icandra, redno pregledovati delovanje ledvic (glejte poglavji 4.4 in 5.2).
Icandra should not be used during pregnancy.
Zdravila Icandra ne smete uporabljati pri nosečnicah.
Children and adolescents The use of Icandra in children and adolescents up to 18 years of age is not recommended.
Otroci in mladostniki Pri otrocih in mladostnikih do 18. leta starosti uporaba zdravila Icandra ni priporočena.
Icandra should not be used in patients with hepatic impairment, including those with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN) (see sections 4.3, 4.4 and 4.8).
Zdravila Icandra ne smejo uporabljati bolniki z okvaro jeter, vključno z bolniki, ki imajo pred zdravljenjem vrednosti alanin-aminotransferaze (ALT) ali aspartat-aminotransferaze (AST) nad 3-kratno zgornjo mejo normalnih vrednosti (upper limit of normal - ULN) (glejte poglavja 4.3, 4.4 in
Should an increase in AST or in ALT of 3x ULN or greater persist, withdrawal of Icandra therapy is recommended.
Če zvišanje AST ali ALT na ali nad 3-kratno zgornjo mejo normalnih vrednosti (ULN - upper limit of normal) vztraja, je priporočena prekinitev zdravljenja z zdravilom Icandra.
Your doctor may want to reduce your dose of the sulphonylurea when you take it together with Icandra in order to avoid low blood glucose (hypoglycaemia).
Zdravnik vam bo morda znižal odmerek sulfoniluree, ki jo boste jemali poleg zdravila Icandra, da ne bi prišlo do zelo nizkih vrednosti glukoze v krvi (hipoglikemija).
Icandra is indicated in the treatment of type 2 diabetes mellitus: - Icandra is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
Zdravilo Icandra je indicirano za zdravljenje bolnikov z diabetesom tipa 2: - Zdravilo Icandra je indicirano za zdravljenje odraslih bolnikov, pri katerih diabetesa ni mogoče urediti samo z metforminom v največjem peroralnem odmerku, ki ga še prenašajo, ali pri tistih, ki že prejemajo zdravljenje z vildagliptinom in metforminom v obliki ločenih tablet.
Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Icandra.
Bolniki, pri katerih pride do ikterusa ali drugih znakov, ki nakazujejo moteno delovanje jeter, morajo prekiniti zdravljenje z zdravilom Icandra.
The recommended dose is one film-coated tablet of either 50 mg/850 mg or 50 mg/1000 mg taken twice a day.
Priporočeni odmerek je ena filmsko obložena tableta bodisi jakosti 50 mg/850 mg ali 50 mg/1000 mg dvakrat na dan.
If you forget to take Icandra
Če ste pozabili vzeti zdravilo Icandra
- For patients switching from co-administration of vildagliptin and metformin as separate tablets: Icandra should be initiated at the dose of vildagliptin and metformin already being taken.
- Za bolnike, ki prehajajo s sočasne uporabe vildagliptina in metformina v obliki ločenih tablet: Zdravilo Icandra naj jemljejo v odmerku, ki ustreza dotedanjima odmerkoma vildagliptina in metformina.
However, bioequivalence of Icandra with co-administered vildagliptin and metformin has been demonstrated (see section 5.2).
Dokazali pa so bioekvivalenco zdravila Icandra s sočasno uporabljanima vildagliptinom in metforminom (glejte poglavje 5.2).
If you stop taking Icandra
Če ste prenehali jemati zdravilo Icandra
When Icandra is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.
Kadar bolnik jemlje zdravilo Icandra v kombinaciji s sulfonilureo, je treba razmisliti o nižjem odmerku sulfoniluree, da bi zmanjšali tveganje za hipoglikemijo.
• Inflammation of the pancreas (pancreatitis) (frequency not known): Symptoms include severe and persistent pain in the abdomen (stomach area), which might reach through to your back as well as nausea and vomiting.
• vnetje trebušne slinavke (pankreatitis) (pogostnost neznana): simptomi vključujejo hudo in trdovratno bolečino v trebuhu (v predelu želodca), ki lahko seva nazaj proti hrbtu, ter občutek slabosti (navzeo) in bruhanje.
Your doctor will decide when you must stop and when to restart your treatment with Icandra.
Zdravnik se bo odločil, kdaj morate z jemanjem zdravila Icandra prenehati in kdaj lahko nadaljujete.
No data are available with regard to overdose of Icandra.
Podatkov o primerih prevelikega odmerjanja zdravila Icandra ni.
Icandra is not recommended for use in children and adolescents (< 18 years).
Uporaba zdravila Icandra pri otrocih in mladostnikih (< 18 let) ni priporočljiva.
LFTs should be performed prior to the initiation of treatment with Icandra in order to know the patient's baseline value.
Pred začetkom zdravljenja z zdravilom Icandra je treba opraviti pregled jetrnih testov za določitev bolnikovih izhodiščnih vrednosti.
Other side effects Some patients have experienced the following side effects while taking Icandra:
Drugi neželeni učinki Pri nekaterih bolnikih je med jemanjem zdravila Icandra prišlo do naslednjih neželenih učinkov:
Some patients have had the following side effects while taking Icandra and insulin:
Pri nekaterih bolnikih je med jemanjem zdravila Icandra in uporabo insulina prišlo do naslednjih neželenih učinkov:
Icandra combines two antihyperglycaemic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: vildagliptin, a member of the islet enhancer class, and metformin hydrochloride, a member of the biguanide class.
Zdravilo Icandra je kombinacija dveh antihiperglikemičnih učinkovin s komplementarnim mehanizmom delovanja za izboljšanje urejenosti glikemije pri bolnikih z diabetesom tipa 2: vildagliptina iz skupine spodbujevalcev Langerhansovih otočkov in metforminijevega klorida iz skupine bigvanidov.
Intravascular administration of iodinated contrast agents may lead to contrast-induced nephropathy, resulting in metformin accumulation and increased risk of lactic acidosis.
Intravaskularna aplikacija jodiranih kontrastnih sredstev lahko povzroči nefropatijo zaradi kontrastnega sredstva, ki povzroči kopičenje metformina in povečano tveganje laktacidoze.
- Icandra is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.
- Zdravilo Icandra je indicirano v kombinaciji s sulfonilureo (torej kot del zdravljenja s trojno kombinacijo zdravil) poleg diete in telesne dejavnosti pri odraslih bolnikih, pri katerih diabetesa ni mogoče ustrezno urediti samo z metforminom in sulfonilureo.
Icandra 50 mg/1000 mg film-coated tablets are dark yellow, oval tablets with “NVR” on one side and “FLO” on the other.
Icandra 50 mg/1000 mg filmsko obložene tablete so temno rumene, ovalne tablete z oznako “NVR” na eni strani in “FLO” na drugi.
Icandra is used to treat adult patients with type 2 diabetes.
Zdravilo Icandra se uporablja za zdravljenje odraslih bolnikov z diabetesom tipa 2, ki se imenuje tudi od insulina neodvisna sladkorna bolezen.
Liver function should be monitored during treatment with Icandra at three-month intervals during the first year and periodically thereafter.
Delovanje jeter je treba v prvem letu zdravljenja z zdravilom Icandra spremljati vsake 3 mesece in občasno tudi kasneje.
How Icandra works
Kako zdravilo Icandra deluje
A test to determine your liver function will be performed before the start of Icandra treatment, at three-month intervals for the first year and periodically thereafter.
Pred začetkom zdravljenja z zdravilom Icandra boste opravili preiskavo delovanja jeter, med zdravljenjem pa boste v prvem letu opravljali kontrolne preiskave na tri mesece in kasneje v rednih časovnih intervalih.
- For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin:
- Za bolnike pri katerih diabetes ni ustrezno urejen z dvojno kombinacijo insulina in najvišjega odmerka metformina, ki ga bolnik še prenaša:
Bioequivalence has been demonstrated between Icandra at three dose strengths (50 mg/500 mg, 50 mg/850 mg and 50 mg/1000 mg) versus free combination of vildagliptin and metformin hydrochloride tablets at the corresponding doses.
Za zdravilo Icandra so dokazali bioekvivalenco treh jakosti (50 mg/500 mg, 50 mg/850 mg in 50 mg/1000 mg) s kombinacijo ločenih tablet vildagliptina in metforminijevega klorida v skladnih odmerkih.
How to take Icandra
Kako jemati zdravilo Icandra
Icandra is available in packs containing 10, 30, 60, 120, 180 or 360 film-coated tablets and in multipacks containing 120 (2x60), 180 (3x60) or 360 (6x60) film-coated tablets.
Zdravilo Icandra je na voljo v pakiranjih po 10, 30, 60, 120, 180 ali 360 filmsko obloženih tablet in v skupnih pakiranjih, ki vsebujejo po 120 (2x60), 180 (3x60) ali 360 (6x60) filmsko obloženih tablet.
A meta-analysis of independently and prospectively adjudicated cardiovascular events from 37 phase III and IV monotherapy and combination therapy clinical studies of up to more than 2 years duration (mean exposure 50 weeks for vildagliptin and 49 weeks for comparators) was performed and showed that vildagliptin treatment was not associated with an increase in cardiovascular risk versus comparators.
Izvedli so metaanalizo podatkov o dogodkih, ki so jih neodvisno in prospektivno ocenili kot kardiovaskularne v37 kliničnih študijah faze III in IV z monoterapijo in s kombinacijo zdravil, ki so trajale do več kot 2 leti (s povprečnim trajanjem izpostavljenosti vildagliptinu 50 tednov, primerjalnim zdravilom pa 49 tednov).
Patients with hepatic impairment, including those with pre-treatment ALT or AST > 3x ULN, should not be treated with Icandra (see sections 4.2, 4.3 and 4.8).
Zdravilo Icandra se ne sme uporabljati pri bolnikih z okvaro jeter, vključno z bolniki, ki imajo pred zdravljenjem vrednosti ALT ali AST nad 3-kratno zgornjo mejo normalnih vrednosti (glejte poglavja 4.2, 4.3 in 4.8).
Polychlorotrifluoroethylene (PCTFE)/PVC/Alu blister Available in packs containing 10, 30, 60, 120, 180 or 360 film-coated tablets and in multi-packs containing 120 (2 packs of 60), 180 (3 packs of 60) or 360 (6 packs of 60) film-coated tablets.
pretisni omot iz poliklorotrifluoretilena (PCTFE)/PVC/Alu) Na voljo so v pakiranjih, ki vsebujejo po 10, 30, 60, 120, 180 ali 360 filmsko obloženih tablet, in v skupnih pakiranjih, ki vsebujejo po 120 (2 pakiranji po 60), 180 (3 pakiranja po 60) ali 360 (6 pakiranj po 60) filmsko obloženih tablet.
- Icandra is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
- Zdravilo Icandra je indicirano kot del zdravljenja s trojno kombinacijo z insulinom poleg diete in telesne dejavnosti pri odraslih bolnikih, pri katerih diabetesa ni mogoče ustrezno urediti samo z metforminom in insulinom v stabilnem odmerku.
If you need to have major surgery you must stop taking Icandra during and for some time after the procedure.
Če morate na večji kirurški poseg, morate v času posega in še nekaj časa po tem prenehati z jemanjem zdravila Eucras.
The dose of Icandra should provide vildagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken.
Z odmerkom zdravila Icandra naj bolnik prejme po 50 mg vildagliptina dvakrat na dan (kar pomeni celotni dnevni odmerek 100 mg vildagliptina) in približno tolikšen odmerek metformina, kot ga je prejemal do tedaj.
You are also advised to pay particular attention to new onset of blisters or ulcers while taking Icandra.
Svetujemo vam tudi, da ste v času jemanja zdravila Icandra posebno pozorni na pojavljanje novega mehurčastega izpuščaja ali novih razjed.
After an oral dose of metformin, the maximum plasma concentration (Cmax) is achieved after about 2.5 h. Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60% in healthy subjects.
Pri zdravih odraslih je absolutna biološka uporabnost 500-miligramske tablete metformina približno 50-60 %.
There have been no formal interaction studies for Icandra.
Formalnih študij medsebojnega delovanja zdravila Icandra z drugimi zdravili niso opravili.
What Icandra looks like and contents of the pack Icandra 50 mg/850 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “SEH” on the other.
Icandra 50 mg/850 mg filmsko obložene tablete so rumene, ovalne tablete z oznako “NVR” na eni strani in “SEH” na drugi.
When and how to take Icandra - Swallow the tablets whole with a glass of water, - Take one tablet in the morning and the other in the evening with or just after food.
• Eno tableto vzemite zjutraj, drugo pa zvečer s hrano ali takoj po njej.
Caution should be exercised in patients with a history of acute pancreatitis.
Pri bolnikih z anamnezo akutnega pankreatitisa je potrebna previdnost.
Icandra 50 mg/850 mg film-coated tablets
Icandra 50 mg/850 mg filmsko obložene tablete
Icandra 50 mg/1000 mg film-coated tablets
Icandra 50 mg/1000 mg filmsko obložene tablete
Adults with normal renal function (GFR ≥ 90 ml/min) The dose of antihyperglycaemic therapy with Icandra should be individualised on the basis of the patient's current regimen, effectiveness and tolerability while not exceeding the maximum recommended daily dose of 100 mg vildagliptin.
Odrasli z normalnim delovanjem ledvic (GFR ≥ 90 ml/min) Odmerek zdravila Icandra za preprečevanje hiperglikemije je treba določiti vsakemu posameznemu bolniku glede na njegovo trenutno shemo zdravljenja in njeno učinkovitost ter glede na bolnikovo prenašanje zdravljenja, pri tem pa se ne sme preseči najvišjega priporočenega dnevnega odmerka vildagliptina 100 mg. Zdravljenje z zdravilom Icandra je mogoče začeti z uporabo tablet bodisi jakosti 50 mg/850 mg ali 50 mg/1000 mg dvakrat dnevno in sicer eno tableto zjutraj, drugo pa zvečer.
Icandra 50 mg/850 mg film-coated tablets Icandra 50 mg/1000 mg film-coated tablets
Icandra 50 mg/850 mg filmsko obložene tablete Icandra 50 mg/1000 mg filmsko obložene tablete
- Each Icandra 50 mg/850 mg film-coated tablet contains 50 mg vildagliptin and 850 mg metformin hydrochloride (corresponding to 660 mg of metformin).
- Ena filmsko obložena tableta Icandra 50 mg/850 mg vsebuje 50 mg vildagliptina in 850 mg metforminijevega klorida (kar ustreza 660 mg metformina).
- Each Icandra 50 mg/1000 mg film-coated tablet contains 50 mg vildagliptin and 1000 mg metformin hydrochloride (corresponding to 780 mg of metformin).
- Ena filmsko obložena tableta Icandra 50 mg/1000 mg vsebuje 50 mg vildagliptina in 1000 mg metforminijevega klorida (kar ustreza 780 mg metformina).
Therefore, you should not receive Icandra for the treatment of type 1 diabetes.
Zdravilo Icandra ni nadomestek insulina, zato zdravila Icandra ne smete prejemati za zdravljenje sladkorne bolezni tipa 1.
Talk to your doctor, pharmacist or nurse before taking Icandra if you have or have had a disease of the pancreas.
Če imate ali ste imeli kdaj prej težave s trebušno slinavko, se pred začetkom jemaja zdravila Icandra posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Talk to your doctor, pharmacist or nurse before taking Icandra if you are taking an anti-diabetic medicine known as a sulphonylurea.
Če jemljete antidiabetično zdravilo, ki ga imenujemo sulfonilurea, se pred začetkom jemanja zdravila Icandra posvetujte s svojim zdravnikom, farmacevtom ali medicinsko sestro.